Assessment of tumor oxygenation and its impact on treatment response in bevacizumab-treated recurrent glioblastoma.

ABSTRACT: Antiantiogenic therapy with bevacizumab in recurrent glioblastoma is currently understood to both reduce microvascular density and to prune abnormal tumor microvessels. Microvascular pruning and the resulting vascular normalization are hypothesized to reduce tumor hypoxia and increase supply of systemic therapy to the tumor; however, the underlying pathophysiological changes and their timing after treatment initiation remain controversial. Here, we use a novel dynamic susceptibility contrast MRI-based method, which allows simultaneous assessment of tumor net oxygenation changes reflected by the tumor metabolic rate of oxygen and vascular normalization represented by the capillary transit time heterogeneity. We find that capillary transit time heterogeneity, and hence the oxygen extraction

SUBMITTER: Bonekamp D 

PROVIDER: S-EPMC5381446 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature